Figure 6.

The effect of LY341495 treatment on the phosphorylated and total levels of GSK-3β, tau and mTOR. Eight week old Fmr1 KO mice and age-matched WT mice were administered LY341495 or vehicle injections for 8 weeks. All data in the top and middle panels are normalized to vehicle-treated WT mice (^*p < 0.05; ^** p < 0.01; ^*** p < 0.001; n over each bar refers to number of mice). (A) Top Panel: There was an increased ratio of phosphorylated GSK-3β (Ser 9) to total GSK-3β in the hippocampus of Fmr1 KO mice compared to WT mice receiving vehicle injection. LY341495 treatment did not alter the phosphorylation in Fmr1 KO or WT mice. Middle Panel: There was no difference between the ratio of total GSK-3β to total α-tubulin in vehicle treated Fmr1 KO and WT mice. LY341495 treatment decreased the levels of total GSK-3β in both Fmr1 KO and WT compared to vehicle treated mice. Bottom Panel: Representative bands of pS9 GSK-3β, total GSK-3β and α-tubulin. (B) Top Panel: There was no difference in the ratio of phosphorylated to total tau at S202 in Fmr1 KO mice compared to WT mice that were vehicle treated. LY341494 treatment reduced the ratio of phosphorylated to total tau in Fmr1 KO and WT mice compared to vehicle treated mice. Middle Panel: There was no difference in total tau protein in Fmr1 KO mice compared to WT mice on vehicle treatment. LY341495 treatment decreased the total tau protein WT mice. Bottom Panel: Representative bands of pS202 tau, total tau and α-tubulin. (C) Top Panel: There was a decreased ratio of phosphorylated to total mTOR at S2448 in Fmr1 KO mice compared to WT mice on vehicle treatment. LY341495 treatment did not change the ratio of phosphorylated to total mTOR in Fmr1 KO or WT mice compared to vehicle treated mice. Middle Panel: There was no difference in total mTOR protein in Fmr1 KO mice compared to WT mice on vehicle treatment. LY341495 treatment did not change the total mTOR protein in Fmr1 KO or WT mice. Bottom Panel: Representative bands of pS2448 mTOR, total mTOR and α-tubulin.